Product Information
QVAR REDIHALER 40 MCG is a brand product labeled by Teva Respiratory, LLC, priced at $20.5659 per GM under NDC 59310030240. Its NADAC has been published 442 times since Apr 18, 2018.
FDA first approved this application on Aug 3, 2017.
Strength
40 ug/1
Manufacturer
Teva Respiratory, LLCNDC
59310030240
Classification
Brand
Dosage Form
AEROSOL, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
BECLOMETHASONE DIPROPIONATEApproval Type
New Drug (NDA)
FDA Application
NDA207921FDA Approved
8/3/2017
On Market Since
2/15/2018
Pharmacological Classes
Price Statistics
The NADAC for QVAR REDIHALER 40 MCG has been published 442 times since Apr 18, 2018, and over the history we have for it it has risen 34.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $20.5659 per GM |
|---|---|
| All-time high | $20.5800 (Jun 10, 2026) |
| All-time low | $15.2549 (Apr 18, 2018) |
| 52-week high | $20.5800 |
| 52-week low | $19.7768 |
| Median price | $18.0668 |
| Average price | $18.1870 |
| Largest weekly change | +6.0% (Jan 8, 2020) |
| Weeks tracked | 442 |
| Tracking since | Apr 18, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Beclomethasone Dipropionate HFA market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Respiratory, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Beclomethasone Dipropionate HFA market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QVAR REDIHALER 40 MCG?
The current National Average Drug Acquisition Cost (NADAC) for QVAR REDIHALER 40 MCG, manufactured by Teva Respiratory, LLC, is $20.5659 per GM (NDC 59310030240), effective Sep 30, 2026.
How has the price of QVAR REDIHALER 40 MCG changed over time?
Over the history we have for it, the NADAC for QVAR REDIHALER 40 MCG has risen 34.8%. It has been tracked across 442 weekly CMS publications since Apr 18, 2018.
What are the highest and lowest recorded NADAC prices for QVAR REDIHALER 40 MCG?
Since Apr 18, 2018, the NADAC for QVAR REDIHALER 40 MCG has ranged from a low of $15.2549 (Apr 18, 2018) to a high of $20.5800 (Jun 10, 2026), with a median of $18.0668 per GM.
Are there cheaper alternatives to QVAR REDIHALER 40 MCG?
No other NADAC-published product currently shares the active ingredient and strength of QVAR REDIHALER 40 MCG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures QVAR REDIHALER 40 MCG?
QVAR REDIHALER 40 MCG (NDC 59310030240) is labeled by Teva Respiratory, LLC, and CMS classifies it as a brand product.